MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.
MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy.
复制标题
DOI：
10.1371/journal.pone.0173060
复制
发表时间：
2017
期刊：
影响因子：
3.7
通讯作者：
Lopes-Cendes I
中科院分区：
文献类型：
--
作者：
Avansini SH;de Sousa Lima BP;Secolin R;Santos ML;Coan AC;Vieira AS;Torres FR;Carvalho BS;Alvim MK;Morita ME;Yasuda CL;Pimentel-Silva LR;Dogini DB;Rogerio F;Cendes F;Lopes-Cendes I
高达25%的癫痫患者被误诊，导致严重和持久的后果。最近，循环microRNA已成为许多临床场景中的潜在生物标志物。本研究的目的是鉴定和验证可用作癫痫诊断生物标志物的循环microRNA。在两个研究阶段中，使用定量实时PCR来测量三种候选microRNA的血浆水平：初始发现阶段，14名内侧颞叶癫痫（MTLE）患者，13名局灶性皮质发育不良（FCD）患者和16名对照;以及由65名MTLE患者和83名对照组成的独立队列组成的验证队列。我们发现，与对照组相比，MTLE患者中hsa-miR-134下调（p = 0.018），但FCD患者中未下调。此外，hsa-miR-134表达可用于区分MTLE患者，曲线下面积（AUC）为0.75。为了进一步评估hsa-miR-134作为MTLE生物标志物的稳健性，我们研究了65例MTLE患者的独立队列，其中27例MTLE患者对药物治疗有反应，38例患者为药物抗性，83例为对照。我们证实，与对照组相比，MTLE患者血浆中的hsa-miR-134显著下调（p < 0.001）。此外，hsa-miR-134识别患有MTLE的患者，而不管他们对药物治疗的反应或海马硬化的MRI体征的存在。我们发现hsa-miR-134的表达降低可能是一种潜在的非侵入性生物标志物，以支持MTLE患者的诊断。
Epilepsy is misdiagnosed in up to 25% of patients, leading to serious and long-lasting consequences. Recently, circulating microRNAs have emerged as potential biomarkers in a number of clinical scenarios. The purpose of this study was to identify and to validate circulating microRNAs that could be used as biomarkers in the diagnosis of epilepsy. Quantitative real-time PCR was used to measure plasma levels of three candidate microRNAs in two phases of study: an initial discovery phase with 14 patients with mesial temporal lobe epilepsy (MTLE), 13 with focal cortical dysplasia (FCD) and 16 controls; and a validation cohort constituted of an independent cohort of 65 patients with MTLE and 83 controls. We found hsa-miR-134 downregulated in patients with MTLE (p = 0.018) but not in patients with FCD, when compared to controls. Furthermore, hsa-miR-134 expression could be used to discriminate MTLE patients with an area under the curve (AUC) of 0.75. To further assess the robustness of hsa-miR-134 as a biomarker for MTLE, we studied an independent cohort of 65 patients with MTLE, 27 of whom MTLE patients were responsive to pharmacotherapy, and 38 patients were pharmacoresistant and 83 controls. We confirmed that hsa-miR-134 was significantly downregulated in the plasma of patients with MTLE when compared with controls (p < 0.001). In addition, hsa-miR-134 identified patients with MTLE regardless of their response to pharmacotherapy or the presence of MRI signs of hippocampal sclerosis. We revealed that decreased expression of hsa-miR-134 could be a potential non-invasive biomarker to support the diagnosis of patients with MTLE.